Navigation Links
Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
Date:9/24/2007

FRAMINGHAM, Mass., Sept. 24 /PRNewswire/ -- Iodine has been used as an antimicrobial for the last century. Much has been written about molecular iodine yet many women suffering from Fibrocystic Breast Disease (FBD) are unaware that studies being conducted may soon yield an effective nonhormonal treatment.

While there are several breast cancer drugs on the market, all available hormonal therapies have significant adverse events. In contrast, IoGen is a nonhormonal treatment that allows for safe long-term use with little or no side effects.

"Current research provides substantive support for the initiation of human clinical studies on the use of molecular iodine as a treatment for breast disease," stated Paul Desjourdy, President and CEO, Symbollon Pharmaceuticals, Inc. "The possibility that IoGen may be used as a treatment for breast cancer makes it all the more important that we expedite the commercialization time line."

The Company believes IoGen has the ability to eliminate excess cell growth in female reproductive tissue, including the breast, ovaries and uterus. Other indications for IoGen include the treatment or prevention of endometriosis, ovarian cysts, and premenopausal breast cancer.

Symbollon Pharmaceuticals, Inc. is now in FDA Phase III clinical trials for the evaluation of IoGen (I2) for pain/tenderness associated with FBD and with potential to treat female reproductive organ cancers.

The importance of (I2) in the treatments for mammary gland dysfunctions has been corroborated in human and animal models.

Seaweeds, containing high quantities of iodine in several chemical forms including (I2), have been associated with low incidences of benign and malignant breast disease in Asian women.

Past studies by independent researchers have supported the possible effectiveness of molecular iodine (I2) as a treatment for breast cancer.

-- Researchers at Drexel University College of Medicine found that

molecular iodine alters the gene expression profile in the human breast

cancer cells. Dr. Bernard Eskin remarked that these changes may be

responsible for molecular iodine's inhibition of breast cancer

promotion that has been repeatedly observed in animal models.

-- Some researchers investigating the connection between breast tissue and

iodine observed that frequent childbirth and a long lactation period

are known to reduce the risk of breast cancer.

Symbollon is now conducting its IoGen (I2) Phase III pivotal pain study. Results are expected in first quarter of 2008. For more information on IoGen(TM), please visit the company's web site at: http://www.symbollon.com/ or http://www.mybreastpain.com.


'/>"/>
SOURCE Symbollon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
8. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
9. Genetic Analysis Systems Enter the Clinical Mainstream
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):